Zealand chief medical officer on abandoned Boehringer collaboration: "We need to look at the data"
Boehringer Ingelheim called off a collaboration to develop amylin analog drugs for obesity and diabetes with Zealand Pharma on Friday. Zealand must now decide whether to develop an amylin analog itself, or scrap the project.
BY KEVIN GRØNNEMANN, TRANSLATED BY CATHERINE BRETT
Zealand Pharma received disappointing news from its collaboration partner Boehringer Ingelheim on Friday evening, when the German pharmaceutical company called off one of the two companies' partnerships to develop new treatments.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
